Benitec Biopharma Inc.
NASDAQ:BNTCBiotechnology
+$0.36 today
- Market cap
- $288.53M
- Beta
- 0.28
- P/E (TTM)
- -12.3
- EPS (TTM)
- -$0.99
Volume 0.13M
Average 0.11M
BNTC Property, Plant & Equipment (Net)
Physical long-term assets such as land, buildings, and machinery, net of accumulated depreciation.
Benitec Biopharma Inc.NASDAQ: BNTC
Property, Plant & Equipment (Net) · Q3 FY2026 · quarter ended Mar 2026
Property, plant & equipment (net) falls 17.4% from a year ago
Property, plant & equipment (net) stood at $916K at the end of Q3 FY2026, down 17.4% from a year earlier and down 10.2% from the prior quarter. Over 3 fiscal years it compounded at -0.1% a year.
Context
- Property, plant & equipment (net) amounted to 0.5% of total assets at the end of Q3 FY2026, down 0.6 pp from a year earlier.
- Property, plant & equipment (net) increased in 1 of the last 3 fiscal years.
What to watch
Whether property, plant & equipment (net) keeps falling in the next quarterly balance sheet after a -17.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Property, Plant & Equipment (Net) history
USD · from the balance sheet
- Latest · FY2025
- 991K USD
- Year-over-year change
- +120.7%
- 4-year CAGR
- +14.5%
| Period | Period end | Property, Plant & Equipment (Net) | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 991K | +120.7% |
| FY2024 | 2024-06-30 | 449K | -26.8% |
| FY2023 | 2023-06-30 | 613K | -38.3% |
| FY2022 | 2022-06-30 | 993K | +72.1% |
| FY2021 | 2021-06-30 | 577K | — |
Property, Plant & Equipment (Net) vs competitors
How BNTC compares with its peers on the latest reported figures
- BNTC's Mar 2026 property, plant & equipment (net) of $916K is the 8th highest of the 10 companies compared; the peer median is $13.83M.
- Its year-over-year change of -17.4% is the 6th highest of 9, against a peer median of -14.4%.
- Property, plant & equipment (net) amounts to 0.5% of total assets for BNTC, versus a peer median of 5.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $134.47M | +17.7% | +30.1% | 25.5% | |
| Mar 2026 | $25.21M | -10.6% | -12.2% | 6.0% | |
| Mar 2026 | $15.13M | -47.1% | -20.1% | 7.1% | |
| Mar 2026 | $14.98M | -15.2% | -14.3% | 5.7% | |
| Mar 2026 | $13.83M | -13.5% | +33.5% | 24.3% | |
| Dec 2025 | $11.5M | -24.0% | -32.4% | 2.2% | |
| Mar 2026 | $4.62M | +14.1% | -6.1% | 4.2% | |
| Mar 2026 | $916K | -17.4% | -0.1% | 0.5% | |
| Mar 2026 | $257K | -22.8% | +97.4% | 0.1% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding BNTC) | $13.83M | -14.4% | -9.2% | 5.7% | |
Competitors are the stored peer set for BNTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Benitec Biopharma Inc.
NASDAQ:BNTC
Intrinsic Alpha fair value
Locked
Current Price
$8.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.